Cyclin-dependent kinase 5 (cdk5): A potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus

Fan Yan Wei, Kazuhito Tomizawa

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine protein kinase, which forms active complexes with p35 or p39 expressed predominantly in neurons. Cdk5 is indispensable for the development of the central nervous system through regulation of neuronal migration. In mature neurons, Cdk5 has been implicated in various signaling transduction pathways, which contribute to functional neuronal activity. It has been widely accepted that aberrant Cdk5 activity induced by the conversion of p35 to p25 plays roles in the pathogenesis of neurodegenerative diseases. Cdk5 also contributes to adaptive changes in the brain related to drug addiction. Moreover, recent studies suggest that Cdk5 plays crucial roles in physiological functions in non-neuronal cells such as glucose-stimulated insulin secretion in pancreatic -cells. The present evidence indicates that Cdk5 might be a potential drug target for the treatment of neurodegenerative diseases, drug abuse and diabetes mellitus. This review focuses on the implication of Cdk5 in the signaling pathways of both neurodegenerative diseases and drug abuse, and the mechanism of Cdk5 involvement in insulin secretion. This review also discusses the possibility of using Cdk5 inhibitors as therapeutic drugs.

Original languageEnglish
Pages (from-to)1070-1074
Number of pages5
JournalMini-Reviews in Medicinal Chemistry
Volume7
Issue number10
DOIs
Publication statusPublished - Oct 1 2007

Fingerprint

Cyclin-Dependent Kinase 5
Neurodegenerative Diseases
Diabetes Mellitus
Substance-Related Disorders
Therapeutics
Insulin
Neurons
Protein-Serine-Threonine Kinases
Pharmaceutical Preparations
Central Nervous System

Keywords

  • Amyloid Hypothesis
  • Amyotrophic Lateral Sclerosis
  • Cdk5 Activators
  • p25 Transgenic Mice
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Cyclin-dependent kinase 5 (cdk5) : A potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus. / Wei, Fan Yan; Tomizawa, Kazuhito.

In: Mini-Reviews in Medicinal Chemistry, Vol. 7, No. 10, 01.10.2007, p. 1070-1074.

Research output: Contribution to journalReview article

@article{6a79e71d830b4bbe8395e023ef94ffcc,
title = "Cyclin-dependent kinase 5 (cdk5): A potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus",
abstract = "Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine protein kinase, which forms active complexes with p35 or p39 expressed predominantly in neurons. Cdk5 is indispensable for the development of the central nervous system through regulation of neuronal migration. In mature neurons, Cdk5 has been implicated in various signaling transduction pathways, which contribute to functional neuronal activity. It has been widely accepted that aberrant Cdk5 activity induced by the conversion of p35 to p25 plays roles in the pathogenesis of neurodegenerative diseases. Cdk5 also contributes to adaptive changes in the brain related to drug addiction. Moreover, recent studies suggest that Cdk5 plays crucial roles in physiological functions in non-neuronal cells such as glucose-stimulated insulin secretion in pancreatic -cells. The present evidence indicates that Cdk5 might be a potential drug target for the treatment of neurodegenerative diseases, drug abuse and diabetes mellitus. This review focuses on the implication of Cdk5 in the signaling pathways of both neurodegenerative diseases and drug abuse, and the mechanism of Cdk5 involvement in insulin secretion. This review also discusses the possibility of using Cdk5 inhibitors as therapeutic drugs.",
keywords = "Amyloid Hypothesis, Amyotrophic Lateral Sclerosis, Cdk5 Activators, p25 Transgenic Mice, Superoxide dismutase 1",
author = "Wei, {Fan Yan} and Kazuhito Tomizawa",
year = "2007",
month = "10",
day = "1",
doi = "10.2174/138955707782110114",
language = "English",
volume = "7",
pages = "1070--1074",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Cyclin-dependent kinase 5 (cdk5)

T2 - A potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus

AU - Wei, Fan Yan

AU - Tomizawa, Kazuhito

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine protein kinase, which forms active complexes with p35 or p39 expressed predominantly in neurons. Cdk5 is indispensable for the development of the central nervous system through regulation of neuronal migration. In mature neurons, Cdk5 has been implicated in various signaling transduction pathways, which contribute to functional neuronal activity. It has been widely accepted that aberrant Cdk5 activity induced by the conversion of p35 to p25 plays roles in the pathogenesis of neurodegenerative diseases. Cdk5 also contributes to adaptive changes in the brain related to drug addiction. Moreover, recent studies suggest that Cdk5 plays crucial roles in physiological functions in non-neuronal cells such as glucose-stimulated insulin secretion in pancreatic -cells. The present evidence indicates that Cdk5 might be a potential drug target for the treatment of neurodegenerative diseases, drug abuse and diabetes mellitus. This review focuses on the implication of Cdk5 in the signaling pathways of both neurodegenerative diseases and drug abuse, and the mechanism of Cdk5 involvement in insulin secretion. This review also discusses the possibility of using Cdk5 inhibitors as therapeutic drugs.

AB - Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine protein kinase, which forms active complexes with p35 or p39 expressed predominantly in neurons. Cdk5 is indispensable for the development of the central nervous system through regulation of neuronal migration. In mature neurons, Cdk5 has been implicated in various signaling transduction pathways, which contribute to functional neuronal activity. It has been widely accepted that aberrant Cdk5 activity induced by the conversion of p35 to p25 plays roles in the pathogenesis of neurodegenerative diseases. Cdk5 also contributes to adaptive changes in the brain related to drug addiction. Moreover, recent studies suggest that Cdk5 plays crucial roles in physiological functions in non-neuronal cells such as glucose-stimulated insulin secretion in pancreatic -cells. The present evidence indicates that Cdk5 might be a potential drug target for the treatment of neurodegenerative diseases, drug abuse and diabetes mellitus. This review focuses on the implication of Cdk5 in the signaling pathways of both neurodegenerative diseases and drug abuse, and the mechanism of Cdk5 involvement in insulin secretion. This review also discusses the possibility of using Cdk5 inhibitors as therapeutic drugs.

KW - Amyloid Hypothesis

KW - Amyotrophic Lateral Sclerosis

KW - Cdk5 Activators

KW - p25 Transgenic Mice

KW - Superoxide dismutase 1

UR - http://www.scopus.com/inward/record.url?scp=35048891437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048891437&partnerID=8YFLogxK

U2 - 10.2174/138955707782110114

DO - 10.2174/138955707782110114

M3 - Review article

C2 - 17979810

AN - SCOPUS:35048891437

VL - 7

SP - 1070

EP - 1074

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 10

ER -